Boston Scientific exits its global heart valve business
2025-05-29 03:40:23
On May 29th, the reporter learned that Boston Scientific has announced the termination of sales of cardiac aortic valve (TAVR) products worldwide due to stricter requirements from regulators in various countries for new clinical trial data after the product is launched. Just last month, Boston Scientific's TAVR valve just held a market meeting in China.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
